Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride for Modulating Fentanyl Liking in Peri-procedural Settings
NCT07348172Phase 1Not yet recruiting
- Sponsor
- Stanford University
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amisulpride (2 arms), sponsored by Stanford University. Primary endpoint: Change in Drug Liking Rating at 5 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
amisulpride
Beyond the preview
Go deeper on NCT07348172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348172.